Fibromyalgia News and Research RSS Feed - Fibromyalgia News and Research

Fibromyalgia syndrome is a common and chronic disorder characterized by widespread muscle pain, fatigue, and multiple tender points. The word Fibromyalgia comes from the Latin term for fibrous tissue (fibro) and the Greek ones for muscle (myo) and pain (algia). Tender points are specific places on the body-on the neck, shoulders, back, hips, and upper and lower extremities-where people with Fibromyalgia feel pain in response to slight pressure. Although Fibromyalgia is often considered an arthritis-related condition, it is not truly a form of arthritis (a disease of the joints) because it does not cause inflammation or damage to the joints, muscles, or other tissues. Like arthritis, however, Fibromyalgia can cause significant pain and fatigue, and it can interfere with a person's ability to carry on daily activities. Also like arthritis, Fibromyalgia is considered a rheumatic condition.

Fibromyalgia affects over 10 million Americans. For unknown reasons, between 80 and 90 percent of those diagnosed with Fibromyalgia are women; however, men and children also can be affected. Most people are diagnosed during middle age, although the symptoms often become present earlier in life. People with certain rheumatic diseases, such as rheumatoid arthritis, systemic lupus erythematosus (commonly called lupus), or ankylosing spondylitis (spinal arthritis) may be more likely to have Fibromyalgia, too.
Potential treatment for sleep disorders suffered by patients with Fibromyalgia, Post-Traumatic Stress Disorder and Traumatic Brain Injury

Potential treatment for sleep disorders suffered by patients with Fibromyalgia, Post-Traumatic Stress Disorder and Traumatic Brain Injury

Seth Lederman, M.D., President and CEO of New York City-based Tonix Pharmaceuticals Holding Corp. (OTCBB:TNXP) says that a good night’s sleep is a potentially powerful, but currently elusive, treatment for the chronic pain and sleep disorders suffered by patients with fibromyalgia (FM), post-traumatic stress disorder (PTSD), traumatic brain injury (TBI) and chronic traumatic encephalopathy (CTE). [More]
Vulvodynia confers risk for other chronic pain syndromes

Vulvodynia confers risk for other chronic pain syndromes

Women who experience vulvodynia are more likely than those without the pain syndrome to have fibromyalgia, interstitial cystitis, and irritable bowel syndrome, research suggests. [More]

Women with vulvodynia more likely to also have other chronic pain conditions

Millions of women suffer from unexplained vulvar pain so severe it can make intercourse, exercise and even sitting unbearable. New research now shows that women with this painful vaginal condition known as vulvodynia are two to three times more likely to also have one or more other chronic pain conditions, including irritable bowel syndrome, fibromyalgia (musculoskeletal pain) and interstitial cystitis (bladder pain). [More]
Encouraging results from Tonix TNX-102 SL clinical trial for fibromyalgia syndrome

Encouraging results from Tonix TNX-102 SL clinical trial for fibromyalgia syndrome

Tonix Pharmaceuticals Holding Corp., a specialty pharmaceutical company developing therapies for challenging disorders of the central nervous system, including fibromyalgia syndrome and post-traumatic stress disorder, announces that the clinical portion of a human study of a solution version of TNX-102 2.4 mg sublingual tablets has completed. [More]

Pfizer’s Lyrica does not affect reproductive function in healthy males

Pfizer Inc. announced today that top-line results for Lyrica (pregabalin) capsules CV Study A0081104 - Assessment of the Impact of Lyrica on Sperm Production in Healthy Volunteers - demonstrate that Lyrica does not affect the reproductive function in healthy males when compared to placebo. [More]

Top-line results in Pfizer's Lyrica long term safety study for Generalized Anxiety Disorder

Pfizer Inc. announced today that top-line results for Lyrica (pregabalin) capsules Study A0081147 - Long Term Safety and Efficacy of Pregabalin in Subjects with Generalized Anxiety Disorder (GAD) - demonstrate that drug discontinuation symptoms were low after tapering Lyrica treatment following three months and six months in GAD patients. [More]

Delaware district court upholds Pfizer's patents for LYRICA to treat pain and seizures

Pfizer Inc. announced today that the United States District Court for the District of Delaware upheld its composition of matter patent and pain and seizure use patents covering LYRICA (pregabalin) capsules CV. With this decision, Pfizer will exclusively provide pregabalin as LYRICA to patients through December 30, 2018 in the U.S., pending generic company appeal and further litigation. [More]
Lifescript introduces new online health center for women with fibromyalgia

Lifescript introduces new online health center for women with fibromyalgia

Lifescript.com, a women's health and wellness website headquartered in Mission Viejo, Calif., has launched a new online Fibromyalgia Health Center, designed to help women treat and reduce the frustrations and pain of fibromyalgia. [More]
D-ribose effective in improving QOL in energy-depleted patients with FMS/CFS

D-ribose effective in improving QOL in energy-depleted patients with FMS/CFS

A new multicenter study published in The Open Pain Journal showed that daily consumption of the pentose carbohydrate D-ribose resulted in an average energy boost of 61 percent among patients diagnosed with Chronic Fatigue Syndrome (CFS) and fibromyalgia (FMS). [More]
Positive data from Tonix's sublingual TNX-102 PK study for fibromyalgia

Positive data from Tonix's sublingual TNX-102 PK study for fibromyalgia

Tonix Pharmaceuticals Holding Corp., a specialty pharmaceutical company developing non-addictive treatments for chronic pain syndromes, including fibromyalgia, today reported positive data from an animal pharmacokinetic study of its novel sublingual formulation of TNX-102, the Company's very low dose cyclobenzaprine. [More]
Pfizer receives FDA approval for Lyrica to manage neuropathic pain associated with SCI

Pfizer receives FDA approval for Lyrica to manage neuropathic pain associated with SCI

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) approved the use of Lyrica (pregabalin) capsules CV for the management of neuropathic pain associated with spinal cord injury. [More]

Positive results from Zalicus Z944 Phase 1 SAD clinical study for chronic inflammatory pain

Zalicus Inc., a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, today announced that it is has successfully completed a Phase 1 single ascending dose (SAD) clinical study with Z944, its novel, oral, T-type calcium channel blocker. [More]
IACFS/ME releases new guidelines for chronic fatigue syndrome

IACFS/ME releases new guidelines for chronic fatigue syndrome

The International Association for Chronic Fatigue Syndrome and Myalgic Encephalomyelitis (IACFS/ME), the largest group of physicians and researchers dedicated to chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME), has released updated care guidelines directed at primary care physicians and other health care providers. [More]
Exercise can add years to a person's life

Exercise can add years to a person's life

A recent study has shown that exercise can add years to a person's life. Still, as we age it can become more tedious and sometimes more difficult to exercise. [More]

Massage therapy effective for knee osteoarthritis, chronic low back pain and fibromyalgia

A growing body of evidence shows massage therapy can be effective for a variety of prevalent health conditions, including the pain of osteoarthritis of the knee, inflammation after exercise, chronic low back pain and fibromyalgia. [More]

Pfizer announces results from Lyrica clinical studies on fibromyalgia

Pfizer Inc. announced today the results of studies on Lyrica (pregabalin) capsules CV presented at the American Pain Society Annual Meeting in Honolulu. [More]
APS honors recipients of Clinical Centers of Excellence in Pain Management Awards

APS honors recipients of Clinical Centers of Excellence in Pain Management Awards

The American Pain Society (APS), today honored the recipients of its sixth annual Clinical Centers of Excellence in Pain Management Awards recognizing the nation's outstanding pain care centers. [More]
Researchers find protein that controls neurotransmission: findings may lead to new drugs to treat neurological disorders

Researchers find protein that controls neurotransmission: findings may lead to new drugs to treat neurological disorders

Scientists at Weill Cornell Medical College have discovered that the single protein -- alpha 2 delta -- exerts a spigot-like function, controlling the volume of neurotransmitters and other chemicals that flow between the synapses of brain neurons. The study, published online in Nature, shows how brain cells talk to each other through these signals, relaying thoughts, feelings and action, and this powerful molecule plays a crucial role in regulating effective communication. [More]

Pfizer terminates Lyrica Phase 3 trial on neuropathic pain associated with HIV neuropathy

Pfizer Inc. announced today that it has stopped a Phase 3 clinical trial of Lyrica (pregabalin) in patients with neuropathic pain associated with HIV neuropathy, a form of nerve damage characterized by burning pain usually beginning in the feet. The decision follows review of a planned interim analysis of the study by the trial's external Data Monitoring Committee. [More]

Pfizer’s Lyrica Phase 3 study on pDPN fails to meet primary endpoint

Pfizer Inc. announced today that a Phase 3 randomized withdrawal design study for Lyrica (pregabalin) in patients with inadequately treated painful diabetic peripheral neuropathy (pDPN) did not meet its primary efficacy endpoint, change in endpoint mean pain score relative to baseline. [More]